Advancing Science in Sickle Cell Disease: Implications for the Future of Ca...

Event Information

Share this event

Date and Time



Hilton Orlando

6001 Destination Parkway

Orlando Ballroom 1; Lower Lobby Level

Orlando, Florida 32819

View Map

Event description


This program is intended for 61st ASH Annual Meeting and Exposition attendees only.

Activity Chair

Kenneth I. Ataga, MD
Professor, Department of Medicine
Division of Hematology and Oncology
Director, Center for Sickle Cell Disease
University of Tennessee Health Science Center
Memphis, TN


Jo Howard, MB BChir
Consultant and Lead Hematologist
Guy’s and St Thomas’ NHS Foundation Trust
London, UK

Julie Kanter, MD
Associate Professor
Division of Hematology and Oncology
Director, Adult Sickle Cell Clinic
University of Alabama School of Medicine
Birmingham, AL

Mark C. Walters, MD
Professor of Pediatrics
University of California San Francisco
San Francisco, CA
Director, Blood and Marrow Transplantation Program
Division of Hematology/Oncology
UCSF Benioff Children's Hospital
Oakland, CA


During this CME lunch symposium, experts will evaluate the latest advances in treatment options for sickle cell disease (SCD) and their benefits to patients, while examining the latest understanding of SCD phenotypes and the implications for treatment selection. Use the provided iPad® to take notes, ask and answer questions, and interact with faculty as they discuss how emerging treatments may impact the current standards of care.


12:00 PM
Registration and Lunch

12:30 PM
Introduction and Pretest
Kenneth I. Ataga, MD

12:40 PM
State of the Science in Sickle Cell Disease
Kenneth I. Ataga, MD

12:55 PM
Rapid-Fire Roundtable - Advancing Science in SCD: How Might It Impact Patient Care?

  • Gene Therapy
    Mark C. Walters, MD

  • P-selectin Blockers
    Julie Kanter, MD

  • HbS Polymerization Inhibitors
    Jo Howard, MB BChir

1:55 PM
How Might Therapeutic Advances Impact the Future of Care?
Kenneth I. Ataga, MD

2:10 PM

2:20 PM
Question and Answer

2:30 PM

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Evaluate the latest advances in treatment options for patients with SCD and how patients may benefit.

  • Examine the latest understanding regarding SCD phenotypes and implications for treatment selection and sequencing.

  • Describe how emerging SCD treatments may impact current standard of care and the role that hematologists may play in patient education.

Target Audience

The intended audience for this activity is hematologists and other health care professionals involved in the management of patients with SCD.

This continuing medical education activity is provided by Vindico Medical Education.

This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.

This activity is preceding the 61st ASH Annual Meeting and Exposition.

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Vindico Medical Education designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all planners, teachers, and authors involved in the development of CME content are required to disclose to the accredited provider their relevant financial relationships. Relevant financial relationships will be disclosed to the activity audience.

Faculty, topics, program schedule, and credit hours are subject to change. Audiotaping or videotaping is prohibited without written permission from the program committee.

Share with friends

Date and Time


Hilton Orlando

6001 Destination Parkway

Orlando Ballroom 1; Lower Lobby Level

Orlando, Florida 32819

View Map

Save This Event

Event Saved